Skip to content

Efficacy of Nalbuphine as adjuvant to Ropivacaine in Ultrasound guided Supraclavicular Brachial Plexus Block – A prospective randomized control trial

Efficacy of Nalbuphine as adjuvant to Ropivacaine in Ultrasound guided Supraclavicular Brachial Plexus Block – A prospective randomized control trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016112
Enrollment
Unknown
Registered
2018-05-12
Start date
2018-05-14
Completion date
Unknown
Last updated
2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical anesthesia

Interventions

Group 2:ropivacaine+nalbuphine 10mg
Group 3:ropivacaine+nalbuphine 20mg

Sponsors

Shiyan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: The American Society of Anesthesiologists (ASA) physical status I and II; aged between 20 to 60 years male and female; Patients undergoing elective orthopedic surgeries of arm, forearm and hand under supraclavicular brachial plexus block.

Exclusion criteria

Exclusion criteria: 1. Patient refusal; 2. any known hypersensitivity or contraindication to ropivacaine, nalbuphine hydrochloride; 3. pregnancy, lactating mothers; 4. hepatic, renal or cardiopulmonary abnormality; 5. alcoholism; 6. diabetes; 7. long-term analgesic therapy, bleeding diathesis, and local skin site infections; 8. Patients having a history of significant neurological, psychiatric, or neuromuscular disorders.

Design outcomes

Primary

MeasureTime frame
Duration of sensory block;Duration of motor block;Onset of sensory block;onset of motor block;

Secondary

MeasureTime frame
Duration of analgesia;Adverse events;

Countries

China

Contacts

Public ContactRan Ran

Shiyan People's Hospital

rmyymzjx@163.com+86 18671910918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026